Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options

Taysha Gene Therapies, Inc.

Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.
Nolan receives option for 1,106,131 shares; 25% vests Dec 16, 2023, remainder monthly over 36 months.
Sukumar Nagendran appointed President & Head of R&D; base $565K, bonus target 50%, option for 790,093 shares with same vesting.
Severance: Nolan gets 18 months salary + 150% target bonus; Nagendran 15 months + 100% target bonus upon qualifying termination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sukumar Nagendran

President and Head of Research and Development

TSHA · Taysha Gene Therapies, Inc.

Effective: 2022-12-16
Filed: January 6, 2023, 6:59 PM ET

the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.

Appointed

Sean Nolan

Chief Executive Officer

TSHA · Taysha Gene Therapies, Inc.

Effective: 2022-12-16
Filed: January 6, 2023, 6:59 PM ET

the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..

Action: appointed
Role: President and Head of Research and Development

Exact text from the filing

the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.

View on SEC.gov

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-003537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.